Also trades as: 0K05.L (LSE) · $vol 0M

$12.59

-0.04 (-0.32%)

Weekly Expected Move ±11.8%

$10 $11 $13 $14 $15

NYSE · Consumer Cyclical · Personal Products & Services · Alpha Radar Strong Buy · Power 68 · $140.0M mcap · 8M float · 2.83% daily turnover · Short 62% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE

51.3 / 100

NoneWeakNarrowWide

Primary source: Intangible Assets · ROIC: -22.9% · 5Y Avg: -2560.6%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. MED shows a Weak competitive edge (51.3/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Intangible Assets. Negative ROIC of -22.9% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

Low

$12

Avg Target

$12

High

Based on 1 analyst ratings (12 mo)

Analyst Recommendations

Strong Buy: 0Buy: 4Hold: 6Sell: 2Strong Sell: 0

Rating Summary

ConsensusHold

Avg Target$12.00

Analysts1

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-02-19	Stephens	—	Initiated	$12	—	+12.0%	$10.71
2024-11-05	D.A. Davidson	Linda Bolton Weiser	$18	$17	-0	-16.7%	$20.40
2024-06-05	D.A. Davidson	Linda Bolton Weiser	$25	$18	-8	-27.0%	$23.97
2024-04-30	D.A. Davidson	Linda Bolton Weiser	Initiated	$25	—	-29.6%	$35.51
2023-06-05	Jefferies	Stephanie Wissink	Initiated	$150	—	+84.7%	$81.22

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

May 22, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. MED receives an overall rating of B. Strongest factors: DCF (5/5), P/B (5/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5).

Rating Change History

Date	From	To
2026-05-22	B-	B
2026-05-20	B	B-
2026-05-04	B-	B
2026-04-01	B	B-
2026-02-19	C	B
2026-02-18	B+	C
2026-02-02	B	B+
2026-01-03	B+	B

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 24 Grade D

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. MED scores highest in Balance Sheet (96/100) and lowest in Growth (12/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

3.95

Safe Zone

Piotroski F-Score

3/9

✗ ✓ ✗ ✓ ✗ ✓ ✗ ✗ ✗

Beneish M-Score

-3.26

Unlikely Manipulator

Ohlson O-Score

-8.10

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

A-

Score: 67.0/100

Trend: Deteriorating

Earnings Quality

—

OCF/NI: -0.19x

Accruals: -8.8%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. MED scores 3.95, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. MED scores 3/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. MED's score of -3.26 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. MED's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. MED receives an estimated rating of A- (score: 67.0/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

-6.92x

PEG

0.01x

P/S

0.40x

P/B

0.70x

P/FCF

-76.24x

P/OCF

30.17x

EV/EBITDA

-21.02x

EV/Revenue

-0.11x

EV/EBIT

3.04x

EV/FCF

26.06x

Earnings Yield

-17.85%

FCF Yield

-1.31%

Shareholder Yield

0.80%

Graham Number

—

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. MED currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

2.470

NI / EBT

Interest Burden

0.642

EBT / EBIT

EBIT Margin

-0.036

EBIT / Rev

Asset Turnover

1.279

Rev / Assets

Equity Multiplier

1.323

Assets / Equity

ROE

-9.8%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. MED's ROE of -9.8% is driven by Asset Turnover (1.279), indicating efficient use of assets to generate revenue. A tax burden ratio of 2.47 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

—

Price/Value

—

Margin of Safety

—

Premium

—

Assessment

Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$12.57

Median 1Y

$8.28

5th Pctile

$3.50

95th Pctile

$19.60

Ann. Volatility

48.9%

25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Daniel R. Chard Chairman & Chief Executive Officer	$1,000,000	$4,567,664	$5,584,551
Anthony E. Tyree Former Chief Business Operations Officer	$415,873	$162,194	$1,484,720
James P. Maloney Chief Financial Officer	$527,085	$700,427	$1,428,396
Nicholas M. Johnson Chief Field Operations Officer	$440,352	$585,163	$1,195,619
Jason L. Groves Chief Legal Officer & Corporate Secretary	$427,781	$568,465	$1,160,452

CEO Pay Ratio

2:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $5,584,551

Avg Employee Cost (SGA/emp): $2,894,000

Employees: 100

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

100

-80.2% YoY

Revenue / Employee

$3,857,880

Rev: $385,788,000

Profit / Employee

$-186,720

NI: $-18,672,000

SGA / Employee

$2,894,000

Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
ROE	1.1%	1.2%	91.2%	91.6%	87.2%	84.0%	80.3%	79.3%	74.4%	67.1%	55.8%	38.0%	16.5%	4.1%	1.0%	-3.4%	1.8%	0.1%	-9.1%	-9.8%	-9.79%
ROA	63.9%	67.1%	48.6%	48.9%	46.5%	44.8%	40.2%	39.7%	37.2%	33.6%	31.8%	21.6%	9.4%	2.3%	0.7%	-2.4%	1.2%	0.1%	-6.9%	-7.4%	-7.40%
ROIC	-24.8%	-26.1%	1.3%	1.3%	1.3%	1.2%	1.5%	1.5%	1.4%	1.3%	1.3%	85.7%	36.7%	8.8%	2.5%	-7.8%	0.4%	-1.1%	-23.2%	-22.9%	-22.91%
ROCE	1.2%	1.3%	94.7%	95.7%	90.2%	87.1%	1.1%	1.0%	98.7%	85.8%	58.1%	37.1%	15.7%	5.0%	1.3%	-2.9%	0.2%	-1.9%	-6.0%	-5.9%	-5.90%
Gross Margin	74.5%	74.3%	73.7%	72.4%	71.0%	72.5%	69.3%	70.6%	71.1%	75.2%	74.0%	72.8%	73.2%	75.4%	74.1%	72.8%	72.6%	69.5%	69.4%	68.1%	68.06%
Operating Margin	15.6%	13.3%	12.4%	13.2%	10.8%	12.3%	9.7%	15.3%	13.1%	10.8%	4.5%	4.5%	-4.7%	1.5%	0.6%	-1.1%	-1.0%	-4.6%	-10.4%	-1.4%	-1.44%
Net Margin	11.9%	10.2%	9.0%	10.0%	8.6%	9.3%	7.9%	11.5%	10.2%	9.8%	3.2%	4.8%	-4.8%	0.8%	0.7%	-0.7%	2.3%	-2.5%	-24.1%	-2.8%	-2.79%
EBITDA Margin	15.9%	13.7%	13.6%	13.8%	11.4%	13.1%	10.6%	16.2%	14.2%	12.3%	6.3%	6.4%	-2.9%	3.8%	3.3%	1.7%	2.8%	0.9%	-5.8%	3.1%	3.14%
FCF Margin	10.2%	6.9%	4.0%	2.5%	4.1%	7.1%	11.1%	13.0%	14.5%	14.3%	13.2%	9.4%	7.1%	5.0%	2.8%	2.5%	-0.5%	0.2%	0.3%	-0.4%	-0.43%
OCF Margin	11.6%	8.6%	6.2%	4.5%	5.8%	8.3%	12.2%	14.0%	15.6%	15.5%	13.8%	10.1%	7.9%	5.9%	4.1%	3.8%	0.9%	1.7%	1.8%	1.1%	1.07%
ROE 3Y Avg	snapshot only																				6.75%
ROE 5Y Avg	snapshot only																				38.61%
ROA 3Y Avg	snapshot only																				3.87%
ROIC 3Y Avg	snapshot only																				28.57%
ROIC Economic	snapshot only																				-5.31%
Cash ROA	snapshot only																				1.45%
Cash ROIC	snapshot only																				7.67%
CROIC	snapshot only																				-3.04%
NOPAT Margin	snapshot only																				-3.21%
Pretax Margin	snapshot only																				-2.34%
R&D / Revenue	snapshot only																				0.32%
SGA / Revenue	snapshot only																				74.82%
SBC / Revenue	snapshot only																				1.02%

Valuation

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
P/E Ratio	19.86	12.88	13.58	10.99	12.09	7.38	8.42	7.66	7.42	6.83	7.39	6.20	8.14	28.66	92.51	-21.09	42.71	605.83	-6.29	-5.60	-6.921
P/S Ratio	2.35	1.44	1.46	1.13	1.14	0.68	0.76	0.71	0.72	0.67	0.69	0.47	0.31	0.31	0.32	0.27	0.32	0.35	0.30	0.32	0.404
P/B Ratio	19.00	12.94	11.00	8.94	9.37	5.51	7.80	7.01	6.36	5.28	3.65	2.08	1.18	1.04	0.92	0.70	0.74	0.72	0.59	0.56	0.701
P/FCF	23.05	20.93	36.91	44.96	27.93	9.60	6.79	5.45	4.94	4.70	5.21	4.96	4.39	6.21	11.37	10.96	-64.16	232.58	93.98	-76.24	-76.241
P/OCF	20.31	16.70	23.56	24.84	19.80	8.24	6.21	5.05	4.60	4.33	4.98	4.62	3.92	5.26	7.91	7.16	37.42	20.89	17.10	30.17	30.172
EV/EBITDA	13.92	8.78	9.57	7.59	8.38	4.90	5.86	5.26	4.99	4.64	4.35	3.10	2.34	3.45	3.03	0.21	0.65	0.42	-22.77	-21.02	-21.018
EV/Revenue	2.22	1.32	1.41	1.08	1.09	0.63	0.72	0.67	0.67	0.62	0.57	0.33	0.14	0.12	0.08	0.00	0.02	0.01	-0.09	-0.11	-0.111
EV/EBIT	14.36	9.02	9.94	7.93	8.83	5.21	6.21	5.59	5.34	5.03	4.80	3.61	3.23	7.56	16.43	-0.22	18.84	-0.94	2.59	3.04	3.038
EV/FCF	21.79	19.25	35.63	43.05	26.80	8.94	6.45	5.14	4.63	4.34	4.30	3.45	2.03	2.42	2.78	0.10	-3.79	6.24	-26.50	26.06	26.062
Earnings Yield	5.0%	7.8%	7.4%	9.1%	8.3%	13.6%	11.9%	13.0%	13.5%	14.7%	13.5%	16.1%	12.3%	3.5%	1.1%	-4.7%	2.3%	0.2%	-15.9%	-17.9%	-17.85%
FCF Yield	4.3%	4.8%	2.7%	2.2%	3.6%	10.4%	14.7%	18.3%	20.3%	21.3%	19.2%	20.2%	22.8%	16.1%	8.8%	9.1%	-1.6%	0.4%	1.1%	-1.3%	-1.31%
PEG Ratio	snapshot only																				0.005
Price/Tangible Book	snapshot only																				0.564
EV/OCF	snapshot only																				-10.314
EV/Gross Profit	snapshot only																				-0.158
Shareholder Yield	snapshot only																				0.80%

Leverage & Solvency

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Current Ratio	2.10	2.10	1.81	1.81	1.81	1.81	1.58	1.58	1.58	1.58	2.43	2.43	2.43	2.43	3.34	3.34	3.34	3.34	4.69	4.69	4.694
Quick Ratio	1.62	1.62	0.75	0.75	0.75	0.75	0.74	0.74	0.74	0.74	1.84	1.84	1.84	1.84	2.68	2.68	2.68	2.68	4.22	4.22	4.224
Debt/Equity	0.07	0.07	0.16	0.16	0.16	0.16	0.17	0.17	0.17	0.17	0.11	0.11	0.11	0.11	0.08	0.08	0.08	0.08	0.08	0.08	0.084
Net Debt/Equity	-1.04	-1.04	-0.38	-0.38	-0.38	-0.38	-0.40	-0.40	-0.40	-0.40	-0.64	-0.64	-0.64	-0.64	-0.70	-0.70	-0.70	-0.70	-0.76	-0.76	-0.757
Debt/Assets	0.04	0.04	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07	0.07	0.07	0.07	0.06	0.06	0.06	0.06	0.07	0.07	0.065
Debt/EBITDA	0.05	0.05	0.14	0.14	0.15	0.15	0.13	0.13	0.14	0.16	0.16	0.23	0.46	0.93	1.03	2.52	1.14	1.66	11.54	9.20	9.202
Net Debt/EBITDA	-0.80	-0.77	-0.34	-0.34	-0.35	-0.36	-0.31	-0.32	-0.33	-0.38	-0.92	-1.36	-2.70	-5.40	-9.38	-22.84	-10.30	-15.10	-103.50	-82.50	-82.504
Interest Coverage	2936.39	1288.60	851.74	626.40	462.25	324.69	263.29	232.57	277.26	414.22	698.35	—	—	—	—	—	—	—	—	—	—
Equity Multiplier	1.76	1.76	1.97	1.97	1.97	1.97	2.04	2.04	2.04	2.04	1.54	1.54	1.54	1.54	1.35	1.35	1.35	1.35	1.29	1.29	1.292
Cash Ratio	snapshot only																				3.894
Cash to Debt	snapshot only																				9.966
FCF to Debt	snapshot only																				-0.088
Defensive Interval	snapshot only																				237.8 days

Efficiency & Turnover

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Asset Turnover	5.40	6.00	4.53	4.75	4.93	4.86	4.47	4.28	3.84	3.41	3.42	2.87	2.46	2.15	2.03	1.83	1.62	1.45	1.43	1.28	1.279
Inventory Turnover	6.38	7.14	3.41	3.61	3.88	3.89	3.07	2.98	2.67	2.34	3.42	2.78	2.31	2.04	3.25	2.92	2.59	2.44	3.53	3.30	3.301
Receivables Turnover	1258.03	1398.48	5226.33	5489.79	5692.34	5613.58	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Payables Turnover	11.10	12.42	7.45	7.88	8.47	8.49	7.39	7.18	6.44	5.65	6.42	5.22	4.35	3.83	5.07	4.56	4.04	3.81	5.80	5.43	5.426
DSO	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0 days
DIO	57	51	107	101	94	94	119	122	137	156	107	131	158	179	112	125	141	149	103	111	110.6 days
DPO	33	29	49	46	43	43	49	51	57	65	57	70	84	95	72	80	90	96	63	67	67.3 days
Cash Conversion Cycle	25	22	58	55	51	51	70	72	80	91	50	61	74	84	40	45	50	54	40	43	43.3 days
Fixed Asset Turnover	snapshot only																				8.999
Cash Velocity	snapshot only																				2.069
Capital Intensity	snapshot only																				0.743

Growth (YoY)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue	67.5%	68.1%	63.2%	46.1%	30.8%	16.0%	4.7%	-4.6%	-17.4%	-25.7%	-32.9%	-41.3%	-43.9%	-44.6%	-43.8%	-39.5%	-37.6%	-36.3%	-36.0%	-36.3%	-36.31%
Net Income	97.5%	66.8%	59.5%	31.3%	4.3%	-4.4%	-12.5%	-14.0%	-15.3%	-20.6%	-30.8%	-52.2%	-77.9%	-93.9%	-97.9%	-1.1%	-87.6%	-96.6%	-9.9%	-1.9%	-1.86%
EPS	96.9%	67.8%	60.6%	34.1%	8.1%	2.0%	-7.0%	-8.1%	-11.3%	-19.8%	-29.8%	-52.5%	-78.0%	-93.9%	-97.9%	-1.1%	-87.7%	-96.6%	-9.9%	-1.8%	-1.85%
FCF	10.2%	-30.5%	-56.7%	-76.8%	-47.6%	19.5%	1.9%	3.9%	1.9%	50.1%	-20.6%	-57.5%	-72.8%	-80.6%	-87.9%	-84.1%	-1.0%	-98.1%	-92.7%	-1.1%	-1.11%
EBITDA	1.1%	75.6%	58.9%	34.2%	7.0%	-0.7%	-12.9%	-14.7%	-14.8%	-23.0%	-28.8%	-51.6%	-74.4%	-85.5%	-88.8%	-93.2%	-70.0%	-59.2%	-90.7%	-71.5%	-71.51%
Op. Income	1.2%	80.5%	61.2%	33.7%	4.7%	-4.0%	-14.5%	-16.2%	-16.1%	-24.5%	-31.6%	-55.9%	-80.2%	-92.8%	-97.7%	-1.1%	-98.6%	-1.5%	-5.9%	-1.2%	-1.22%
OCF Growth	snapshot only																				-81.96%
Asset Growth	snapshot only																				-9.57%
Equity Growth	snapshot only																				-5.33%
Debt Growth	snapshot only																				4.09%
Shares Change	snapshot only																				0.53%
Dividend Growth	snapshot only																				-55.78%

Growth (CAGR)

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue 3Y	50.7%	48.3%	45.0%	41.3%	37.6%	33.5%	30.8%	28.2%	21.8%	13.2%	4.7%	-6.5%	-15.4%	-21.9%	-26.6%	-30.3%	-33.9%	-36.0%	-37.7%	-39.1%	-39.07%
Revenue 5Y	36.2%	38.9%	40.9%	42.5%	43.1%	41.8%	39.6%	35.9%	29.9%	23.0%	16.4%	9.6%	3.8%	-0.4%	-3.3%	-5.6%	-8.7%	-12.6%	-16.2%	-20.6%	-20.60%
EPS 3Y	56.4%	50.6%	44.2%	39.1%	32.8%	30.8%	25.7%	26.7%	23.6%	11.1%	1.6%	-16.3%	-40.4%	-63.2%	-76.1%	—	-71.2%	-88.2%	—	—	—
EPS 5Y	54.7%	55.6%	56.4%	53.9%	47.2%	46.5%	41.5%	36.1%	29.7%	22.8%	14.4%	3.3%	-14.5%	-35.8%	-50.7%	—	-44.8%	-69.1%	—	—	—
Net Income 3Y	55.1%	49.3%	43.3%	36.8%	29.9%	27.0%	22.6%	23.3%	20.4%	8.2%	-1.1%	-18.6%	-42.0%	-64.1%	-76.6%	—	-71.5%	-88.2%	—	—	—
Net Income 5Y	54.6%	55.1%	55.9%	52.9%	45.7%	43.8%	38.9%	33.2%	26.9%	20.4%	12.2%	1.0%	-16.3%	-37.0%	-51.5%	—	-45.6%	-69.6%	—	—	—
EBITDA 3Y	53.3%	49.9%	45.1%	39.8%	32.0%	29.2%	26.2%	26.5%	24.0%	10.3%	-0.5%	-17.9%	-38.4%	-51.9%	-58.9%	-69.6%	-59.7%	-64.2%	-80.5%	-78.9%	-78.92%
EBITDA 5Y	45.4%	46.4%	47.4%	46.3%	40.3%	38.8%	34.9%	31.1%	26.9%	20.8%	13.7%	2.4%	-12.9%	-24.7%	-30.7%	-41.8%	-31.9%	-39.7%	-60.0%	-59.6%	-59.63%
Gross Profit 3Y	49.9%	47.0%	43.7%	40.0%	35.9%	31.8%	28.5%	25.6%	19.8%	11.5%	3.6%	-6.8%	-15.5%	-22.0%	-26.7%	-30.2%	-33.6%	-36.0%	-37.7%	-39.3%	-39.29%
Gross Profit 5Y	36.3%	38.8%	40.5%	41.9%	42.0%	40.6%	38.0%	34.1%	28.2%	21.3%	15.4%	8.8%	3.4%	-0.8%	-3.7%	-6.0%	-8.9%	-13.1%	-17.0%	-21.4%	-21.44%
Op. Income 3Y	56.3%	52.3%	46.3%	40.3%	32.1%	29.3%	26.6%	26.8%	24.1%	9.4%	-2.0%	-20.9%	-44.2%	-62.6%	-76.3%	—	-86.7%	—	—	—	—
Op. Income 5Y	51.3%	51.7%	51.8%	49.6%	42.2%	40.2%	36.1%	32.0%	27.4%	20.7%	12.9%	0.4%	-17.4%	-34.8%	-49.9%	—	-64.8%	—	—	—	—
FCF 3Y	31.7%	23.7%	2.6%	-15.8%	4.4%	18.6%	33.8%	40.1%	19.3%	7.6%	0.4%	-21.3%	-25.1%	-29.7%	-34.4%	-30.6%	—	-82.3%	-80.9%	—	—
FCF 5Y	35.8%	31.7%	21.8%	13.8%	22.9%	31.3%	34.8%	31.6%	28.6%	27.7%	20.4%	4.7%	-1.8%	-13.4%	-25.5%	-28.6%	—	-65.9%	-61.0%	—	—
OCF 3Y	34.1%	30.0%	15.8%	-1.2%	11.3%	18.9%	32.2%	40.0%	20.9%	9.3%	0.6%	-20.9%	-25.5%	-31.0%	-36.3%	-34.4%	-64.9%	-62.4%	-67.2%	-74.1%	-74.14%
OCF 5Y	37.2%	34.4%	30.1%	24.5%	28.5%	32.7%	35.1%	31.6%	28.6%	27.8%	19.4%	3.8%	-2.6%	-13.1%	-21.9%	-23.4%	-49.1%	-45.1%	-45.7%	-54.2%	-54.17%
Assets 3Y	23.7%	23.7%	33.0%	33.0%	33.0%	33.0%	17.6%	17.6%	17.6%	17.6%	3.9%	3.9%	3.9%	3.9%	-10.6%	-10.6%	-10.6%	-10.6%	-6.7%	-6.7%	-6.68%
Assets 5Y	18.7%	18.7%	26.9%	26.9%	26.9%	26.9%	16.7%	16.7%	16.7%	16.7%	12.8%	12.8%	12.8%	12.8%	7.9%	7.9%	7.9%	7.9%	-1.4%	-1.4%	-1.42%
Equity 3Y	13.1%	13.1%	22.9%	22.9%	22.9%	22.9%	13.9%	13.9%	13.9%	13.9%	8.6%	8.6%	8.6%	8.6%	1.2%	1.2%	1.2%	1.2%	8.7%	8.7%	8.66%
Book Value 3Y	14.1%	14.1%	23.7%	25.0%	25.6%	26.6%	16.8%	17.1%	17.0%	17.1%	11.6%	11.6%	11.6%	11.2%	3.6%	3.3%	2.4%	1.4%	9.0%	8.3%	8.31%
Dividend 3Y	9.6%	8.3%	7.0%	9.8%	9.3%	8.7%	6.5%	6.2%	4.4%	3.8%	3.4%	-7.2%	-18.3%	-35.0%	-78.1%	-84.3%	-82.3%	-78.1%	-35.0%	-24.1%	-24.06%

Growth Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Revenue Stability	0.84	0.86	0.88	0.91	0.93	0.95	0.95	0.93	0.83	0.68	0.49	0.25	0.07	0.00	0.01	0.04	0.10	0.21	0.35	0.57	0.568
Earnings Stability	0.87	0.92	0.94	0.96	0.93	0.94	0.91	0.88	0.77	0.65	0.40	0.10	0.00	0.06	0.15	0.27	0.38	0.54	0.67	0.80	0.805
Margin Stability	0.99	0.99	0.99	0.99	0.98	0.98	0.98	0.97	0.97	0.97	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.975
Rev. Growth Consistency	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.000
Earn. Growth Consistency	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.000
FCF Positive Streak	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	0	0
Earnings Persistence	0.50	0.50	0.50	0.87	0.98	0.98	0.95	0.94	0.94	0.92	0.88	0.50	0.50	0.50	0.50	0.20	0.50	0.50	0.20	0.50	0.500
Earnings Smoothness	0.34	0.50	0.54	0.73	0.96	0.96	0.87	0.85	0.83	0.77	0.64	0.29	0.00	0.00	0.00	—	0.00	0.00	—	—	—
ROE Trend	0.27	0.22	0.11	0.05	-0.07	-0.21	0.19	0.11	-0.01	-0.10	-0.37	-0.53	-0.67	-0.72	-0.70	-0.66	-0.48	-0.40	-0.35	-0.25	-0.252
Gross Margin Trend	-0.01	-0.01	-0.01	-0.01	-0.02	-0.02	-0.03	-0.03	-0.03	-0.02	-0.00	0.01	0.02	0.02	0.02	0.02	0.01	-0.00	-0.02	-0.03	-0.034
FCF Margin Trend	-0.02	-0.06	-0.09	-0.10	-0.09	-0.05	0.02	0.04	0.07	0.07	0.06	0.02	-0.02	-0.06	-0.09	-0.09	-0.11	-0.10	-0.08	-0.06	-0.064
Sustainable Growth Rate	71.5%	74.7%	55.7%	54.3%	48.7%	44.7%	40.2%	37.8%	33.5%	26.3%	14.8%	7.4%	-4.2%	-6.4%	0.7%	—	1.7%	0.0%	—	—	—
Internal Growth Rate	66.2%	71.2%	42.3%	40.7%	35.1%	31.3%	25.2%	23.4%	20.2%	15.1%	9.2%	4.4%	—	—	0.5%	—	1.2%	0.0%	—	—	—

Cash Flow Quality

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
OCF/Net Income	0.98	0.77	0.58	0.44	0.61	0.90	1.36	1.52	1.61	1.58	1.49	1.34	2.07	5.45	11.70	-2.94	1.14	29.01	-0.37	-0.19	-0.186
FCF/OCF	0.88	0.80	0.64	0.55	0.71	0.86	0.91	0.93	0.93	0.92	0.96	0.93	0.89	0.85	0.70	0.65	-0.58	0.09	0.18	-0.40	-0.396
FCF/Net Income	snapshot only																				0.073
OCF/EBITDA	snapshot only																				2.038
CapEx/Revenue	1.4%	1.7%	2.2%	2.0%	1.7%	1.2%	1.0%	1.0%	1.1%	1.2%	0.6%	0.7%	0.8%	0.9%	1.2%	1.3%	1.4%	1.5%	1.5%	1.5%	1.50%
CapEx/Depreciation	snapshot only																				0.359
Accruals Ratio	0.01	0.15	0.21	0.27	0.18	0.05	-0.14	-0.20	-0.23	-0.19	-0.15	-0.07	-0.10	-0.10	-0.08	-0.09	-0.00	-0.02	-0.09	-0.09	-0.088
Sloan Accruals	snapshot only																				-0.022
Cash Flow Adequacy	snapshot only																				0.705

Dividends & Buybacks

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Dividend Yield	1.9%	3.0%	2.9%	3.7%	3.7%	6.3%	5.9%	6.8%	7.4%	8.9%	9.9%	13.0%	15.4%	8.9%	0.4%	0.1%	0.1%	0.1%	0.2%	0.1%	0.00%
Dividend/Share	$4.78	$5.10	$5.42	$5.77	$6.07	$6.40	$6.46	$6.80	$6.69	$6.67	$6.68	$4.98	$3.36	$1.70	$0.07	$0.02	$0.02	$0.02	$0.02	$0.01	$0.00
Payout Ratio	37.7%	38.1%	38.9%	40.7%	44.2%	46.8%	49.9%	52.3%	54.9%	60.9%	73.4%	80.5%	1.3%	2.6%	34.2%	—	5.4%	78.6%	—	—	—
FCF Payout Ratio	43.7%	61.9%	1.1%	1.7%	1.0%	60.9%	40.3%	37.2%	36.6%	41.9%	51.7%	64.4%	67.5%	55.3%	4.2%	1.5%	—	30.2%	15.6%	—	—
Total Payout Ratio	52.1%	68.4%	76.8%	79.7%	1.5%	1.4%	1.4%	1.4%	64.9%	72.0%	80.4%	81.9%	1.3%	2.7%	74.1%	—	15.6%	2.3%	—	—	—
Div. Increase Streak	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
Chowder Number	0.30	0.27	0.23	0.30	0.26	0.24	0.18	0.17	0.13	0.12	0.12	-0.13	-0.34	-0.65	-0.99	-1.00	-0.99	-0.99	-0.73	-0.56	-0.557
Buyback Yield	0.7%	2.4%	2.8%	3.5%	8.5%	12.2%	10.6%	11.4%	1.3%	1.6%	0.9%	0.2%	0.4%	0.4%	0.4%	0.3%	0.2%	0.2%	0.3%	0.7%	0.73%
Net Buyback Yield	0.7%	2.4%	2.8%	3.5%	8.5%	12.2%	10.6%	11.4%	1.3%	1.6%	0.9%	0.2%	0.4%	0.4%	0.4%	0.3%	0.2%	0.2%	0.3%	0.7%	0.73%
Total Shareholder Return	2.6%	5.3%	5.7%	7.3%	12.2%	18.5%	16.5%	18.2%	8.8%	10.5%	10.9%	13.2%	15.8%	9.3%	0.8%	0.4%	0.4%	0.4%	0.5%	0.8%	0.80%

DuPont Factors

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Tax Burden (NI/EBT)	0.77	0.76	0.76	0.75	0.76	0.76	0.78	0.78	0.77	0.79	0.77	0.78	0.79	0.59	0.55	0.96	0.58	0.12	3.31	2.47	2.470
Interest Burden (EBT/EBIT)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.01	1.02	1.08	1.09	1.14	1.32	1.15	12.84	-0.47	0.44	0.64	0.642
EBIT Margin	0.15	0.15	0.14	0.14	0.12	0.12	0.12	0.12	0.13	0.12	0.12	0.09	0.04	0.02	0.00	-0.01	0.00	-0.01	-0.03	-0.04	-0.036
Asset Turnover	5.40	6.00	4.53	4.75	4.93	4.86	4.47	4.28	3.84	3.41	3.42	2.87	2.46	2.15	2.03	1.83	1.62	1.45	1.43	1.28	1.279
Equity Multiplier	1.80	1.80	1.87	1.87	1.87	1.87	2.00	2.00	2.00	2.00	1.76	1.76	1.76	1.76	1.44	1.44	1.44	1.44	1.32	1.32	1.323

Per Share

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
EPS (Diluted TTM)	$12.69	$13.41	$13.92	$14.16	$13.72	$13.68	$12.95	$13.01	$12.18	$10.97	$9.09	$6.18	$2.68	$0.67	$0.19	$-0.64	$0.33	$0.02	$-1.70	$-1.82	$-1.82
Book Value/Share	$13.26	$13.34	$17.18	$17.40	$17.71	$18.34	$13.98	$14.23	$14.20	$14.18	$18.43	$18.39	$18.42	$18.36	$19.13	$19.19	$19.00	$19.12	$18.10	$18.07	$17.96
Tangible Book/Share	$13.26	$13.34	$17.18	$17.40	$17.71	$18.34	$13.98	$14.23	$14.20	$14.18	$18.43	$18.39	$18.42	$18.36	$19.13	$19.19	$19.00	$19.12	$18.10	$18.07	$18.07
Revenue/Share	$107.21	$119.91	$129.49	$137.74	$145.36	$148.45	$144.18	$140.38	$125.75	$111.43	$98.04	$81.93	$70.42	$61.48	$54.85	$49.64	$43.44	$39.10	$35.10	$31.45	$31.45
FCF/Share	$10.93	$8.25	$5.12	$3.46	$5.94	$10.52	$16.04	$18.27	$18.29	$15.94	$12.91	$7.73	$4.97	$3.08	$1.55	$1.23	$-0.22	$0.06	$0.11	$-0.13	$-0.13
OCF/Share	$12.41	$10.34	$8.02	$6.26	$8.38	$12.26	$17.55	$19.72	$19.63	$17.28	$13.50	$8.29	$5.56	$3.64	$2.23	$1.88	$0.38	$0.65	$0.62	$0.34	$0.34
Cash/Share	$14.71	$14.80	$9.30	$9.41	$9.58	$9.92	$7.91	$8.05	$8.03	$8.02	$13.72	$13.69	$13.72	$13.68	$14.78	$14.83	$14.68	$14.77	$15.22	$15.20	$15.35
EBITDA/Share	$17.12	$18.09	$19.07	$19.62	$19.00	$19.17	$17.66	$17.87	$16.96	$14.92	$12.76	$8.60	$4.33	$2.16	$1.42	$0.58	$1.28	$0.88	$0.13	$0.17	$0.17
Debt/Share	$0.94	$0.95	$2.76	$2.80	$2.85	$2.95	$2.35	$2.39	$2.39	$2.38	$2.01	$2.01	$2.01	$2.01	$1.47	$1.47	$1.46	$1.47	$1.53	$1.53	$1.53
Net Debt/Share	$-13.77	$-13.86	$-6.53	$-6.62	$-6.73	$-6.97	$-5.56	$-5.66	$-5.65	$-5.64	$-11.71	$-11.68	$-11.71	$-11.67	$-13.31	$-13.36	$-13.22	$-13.30	$-13.69	$-13.67	$-13.67

Academic Models

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.946
Altman Z-Prime	snapshot only																				7.756
Piotroski F-Score	7	7	6	6	5	4	5	5	5	5	6	5	5	5	5	4	4	4	3	3	3
Beneish M-Score	-2.13	-1.76	-1.66	-1.59	-1.99	-2.71	-2.95	-3.34	-3.65	-3.54	-3.63	-3.31	-3.39	-3.34	-3.13	-3.19	-2.75	-2.81	-3.33	-3.26	-3.260
Ohlson O-Score	snapshot only																				-8.102
ROIC (Greenblatt)	snapshot only																				-6.40%
Net-Net WC	snapshot only																				$13.05
EVA	snapshot only																				$-15938750.00

Credit

Metric	Q2'21	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Current
Credit Rating	snapshot only																				A-
Credit Score	97.35	97.29	97.44	96.84	97.02	97.22	97.35	97.43	97.48	96.99	97.10	94.20	93.95	93.60	91.60	76.06	87.00	76.17	70.13	66.96	66.960
Credit Grade	snapshot only																				7
Credit Trend	snapshot only																				-9.096
Implied Spread (bps)	snapshot only																				175.000
Industry Credit Rank	snapshot only																				76
Sector Credit Rank	snapshot only																				56

MED NYSE

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet